Samsung Biologics, LegoChem team up to develop... > 경제기사 | natenews rank

Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, will collaborate with LegoChem Biosciences Inc. to develop antibody-drug conjugate ADC therapeutics.

Samsung Biologics announced on Wednesday that it has signed a contract development organization CDO agreement with LegoChem, a leading ADC player in Korea.

Under the agreement, Samsung Biologics will provide LegoChem with comprehensive CDO-related services, from cell line development to clinical material production.

“Collaboration between Samsung Biologics and LegoChem Biosciences will enable us to deliver on our common goal to develop and manufacture efficient and safe therapeutics for patients,” said John Rim, chief executive officer and president of Samsung Biologics. “We look forward to working with LegoChem Biosciences to support their pipeline of innovative ADC candidates and secure new opportunities in the fast-growing ADC field.”

LegoChem, founded in 2006, has distinctive research and development Ramp;D capabilities in ADC technology and synthetic new drug areas. It has signed a total of 13 technology transfer agreements with global pharmaceutical companies, amounting to a maximum of 8.7 trillion won $6.55 billion.

“LegoChem Biosciences had previously supplied antibodies for ADC through only overseas companies, but we expect that we will be able to secure a stable domestic supply chain through this contract,” said Kim Yong-zu, CEO and president of LegoChem Biosciences.

▶ “나도 月100만원 평생 받을 수 있었네”…국민연금 분할수급자 7만명 돌파[언제까지 직장인]

▶ “한 번 지나가면 흔적도 안 남아”…삼성 도대체 뭘 만든 거야

▶ “이게 성과급? 장난하나”…‘더 올려달라’ 인상 요구에 대기업 ‘난감’

▶ 이재용 회장 딸 원주씨 美 NGO단체서 인턴 활동, 자기소개서 보니

▶ “3년 백수를, 한국이 자폭”…1년전 ‘클린스만 발탁’ 전한 獨매체, 눈길